EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that 21,614,766 share options over ordinary shares have been cancelled.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, wishes to update shareholders on its current trading and the proposals it set out in its announcement on 20 March 2017.
EKF Diagnostics Holdings plc announces that the Directors are currently evaluating plans under which they would split the Company into two separate companies.
EKF Diagnostics Holdings plc is pleased to announce its final results for the year ended 31 December 2016.
EKF Diagnostics announces that it will release its preliminary results on 21 March 2017.